Thermo Fisher falls as 2026 profit midpoint trails estimates

Shares of medical equipment maker Thermo Fisher Scientific TMO.N fall 5% to $577 premarket

Co expects 2026 adjusted EPS at $24.22–$24.80; midpoint of $24.51 sits below analysts’ avg estimate of $24.61 – data compiled by LSEG

Co forecasts 2026 revenue of $46.3 bln–$47.2 bln; analysts’ avg estimate is $46.54 bln

Q4 revenue of $12.22 bln compared with estimate of $11.95 bln

Exec says Asia Pacific grew low-single-digit in 2025; China declined by mid-single-digit

Up to previous close, stock had risen 4.1% in the last 12 months